Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPX-121
- Development stage
- Unknown
- Lead developer
- Tego Science
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intradermal
01
Overview
TPX-121 is an allogeneic cell therapy consisting of cultured dermal fibroblasts, developed by Tego Science for the aesthetic treatment of facial wrinkles, specifically hypoplastic nasolabial folds. The therapy functions by replenishing the fibroblast population in the dermal layer, which in turn promotes the synthesis of essential extracellular matrix components such as collagen and elastin to restore skin structure and volume. While Tego Science's pipeline categorizes TPX-121 as being in preclinical development for wrinkles, clinical trial evidence (NCT06533540) indicates that the associated allogeneic fibroblast product, TPX-115, is being evaluated in Phase 1 trials for nasolabial folds. Efficacy in these studies is typically measured using standardized scales including the Wrinkle Severity Rating Scale (WSRS) and the Global Aesthetic Improvement Scale (GAIS).
- Other names
- allogeneic dermal fibroblasts
Beyond the preview
Go deeper on TPX-121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPX-121.